Launched in 2016 by tech entrepreneur Sean Parker, the Parker Institute for Cancer Immunotherapy (PICI) is a collaboration of the country’s leading immunologists and cancer treatment centers dedicated to building a smarter and more coordinated cancer immunotherapy research effort.

In 2016, PICI and the Cancer Research Institute announced their partnership to create the Tumor neoantigEn SeLection Alliance (TESLA), a collaboration of 30 of the world’s leading cancer neoantigen research groups from academia and industry to identify optimal targets for personalized cancer immunotherapy.

*Immunotherapy results may vary from patient to patient.